Early skin disease drug trial halted
NCT ID NCT06005792
Summary
This early-stage study aimed to test the safety and side effects of a new drug called XmAb27564 in people with plaque psoriasis and atopic dermatitis (eczema). Participants received four injections of either the drug or a placebo over several weeks. The study was terminated early, and its main goal was to understand how the body handles the drug and if it was safe, not to prove it worked.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Clinical Studies, LTD. LLP
Webster, Texas, 77598, United States
-
Clinical Trials Research Institute
Thousand Oaks, California, 91320, United States
-
Driven Research
Coral Gables, Florida, 33134, United States
-
Innovaderm Research Inc.
Montreal, Quebec, H2X 2V1, Canada
-
J&S Studies, Inc
College Station, Texas, 77845, United States
-
San Marcus Research Clinic
Miami Lakes, Florida, 33104, United States
-
Unison Clinical Trials
Sherman Oaks, California, 91403, United States
Conditions
Explore the condition pages connected to this study.